Genocea Biosciences
Develops key breakthroughs in human vaccine discovery and development for antigens that induce T cell immunity.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | $80.0m | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | 100 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (20000 %) | - | - | - | (4600 %) | (2600 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (20833 %) | - | - | - | (4400 %) | (1650 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Genocea Biosciences, based in Cambridge, is a pioneering bioscience company focused on developing personalized cancer vaccines and immunotherapies. The company operates in the biotechnology sector, specifically targeting cancer treatment through its innovative ATLAS platform. This platform identifies true T cell antigens, enabling the creation of tailored immunotherapies that are as unique as the individual cancers they target. Genocea's primary clients are cancer patients and healthcare providers seeking advanced treatment options. The company generates revenue through the development and commercialization of its proprietary cancer vaccines and immunotherapies. Genocea's business model involves extensive research and development, clinical trials, and partnerships with healthcare institutions to bring its therapies to market. The company's mission is to conquer cancer by leveraging the immune system's ability to recognize and fight cancer cells.
Keywords: personalized cancer vaccines, neoantigen immunotherapies, T cell antigens, ATLAS platform, biotechnology, cancer treatment, healthcare providers, immunotherapy efficacy, clinical trials, bioscience.